TY - T1的早期访问bedaquiline extensively drug-resistant (XDR) and pre-XDR tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02208-2018 VL - 54 IS - 1 SP - 1802208 AU - Vasilyeva, Irina AU - Mariandyshev, Andrei AU - Kazennyy, Boris AU - Davidavičienė, Edita AU - Lounis, Nacer AU - Keim, Sofia A2 - , Y1 - 2019/07/01 UR - //www.qdcxjkg.com/content/54/1/1802208.abstract N2 - Globally in 2016, 19% of previously treated tuberculosis (TB) cases and 4.1% of newly diagnosed cases were reported to be resistant to isoniazid and rifampicin (multidrug-resistant (MDR)-TB) or rifampicin alone (rifampicin-resistant TB) [1]. In 2017, 8.5% of MDR-TB cases were caused by extensively drug-resistant (XDR)-TB [1], defined as MDR-TB with additional resistance to a fluoroquinolone (FQ) and a second-line injectable drug (SLI) (amikacin, kanamycin or capreomycin). TB drug resistance, especially XDR-TB, is associated with poorer treatment outcomes [1–3].This letter presents final safety and efficacy data from an early-access study of bedaquiline for treating (pre-)XDR-TB http://bit.ly/2Ff4qylWe would like to express gratitude to the patients and their families for their participation and support during the study. We would also like to thank the study centre staff and public health authorities for their support. We are grateful to all the Janssen study personnel, as well as Nyasha Bakare and other Janssen staff members for their review of this letter, and Chris Liu, previously a contractor with Johnson & Johnson, who was involved in the data analysis. Medical writing support was provided by Ian Woolveridge of Zoetic Science, an Ashfield company, Macclesfield, UK; this support was funded by Janssen. ER -